Published in J Exp Med on May 01, 1990
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med (1998) 11.03
Precise prediction of a dominant class I MHC-restricted epitope of Listeria monocytogenes. Nature (1991) 3.80
Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide. Proc Natl Acad Sci U S A (1991) 3.15
A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med (1992) 2.92
Influenza virus-infected dendritic cells stimulate strong proliferative and cytolytic responses from human CD8+ T cells. J Clin Invest (1994) 2.57
On the role of antigen in maintaining cytotoxic T-cell memory. Proc Natl Acad Sci U S A (1996) 2.55
T cell priming versus T cell tolerance induced by synthetic peptides. J Exp Med (1995) 2.07
Peptide-induced antiviral protection by cytotoxic T cells. Proc Natl Acad Sci U S A (1991) 1.89
A "string-of-beads" vaccine, comprising linked minigenes, confers protection from lethal-dose virus challenge. J Virol (1993) 1.86
Resting memory CD8+ T cells are hyperreactive to antigenic challenge in vitro. J Exp Med (1996) 1.83
Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J Clin Invest (1995) 1.78
Definition of a minimal optimal cytotoxic T-cell epitope within the hepatitis B virus nucleocapsid protein. J Virol (1993) 1.74
DNA immunization: ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction. J Virol (1997) 1.69
Cognate peptides induce self-destruction of CD8+ cytolytic T lymphocytes. Proc Natl Acad Sci U S A (1990) 1.63
Dendritic cells efficiently induce protective antiviral immunity. J Virol (1998) 1.53
Insertion signal sequence fused to minimal peptides elicits specific CD8+ T-cell responses and prolongs survival of thymoma-bearing mice. Cancer Res (1994) 1.48
In vivo induction of a high-avidity, high-frequency cytotoxic T-lymphocyte response is associated with antiviral protective immunity. J Virol (2000) 1.45
Cellular and humoral antigenic epitopes in HIV and SIV. Immunology (1992) 1.38
Extracellular processing of peptide antigens that bind class I major histocompatibility molecules. J Exp Med (1992) 1.32
Formalin inactivation of vesicular stomatitis virus impairs T-cell- but not T-help-independent B-cell responses. J Virol (1993) 1.30
Anti-viral protection conferred by recombinant adenylate cyclase toxins from Bordetella pertussis carrying a CD8+ T cell epitope from lymphocytic choriomeningitis virus. Proc Natl Acad Sci U S A (1997) 1.28
Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells. Proc Natl Acad Sci U S A (1997) 1.23
Generation of cytotoxic and humoral immune responses by nonreplicative recombinant Semliki Forest virus. Proc Natl Acad Sci U S A (1995) 1.21
Cell-invasive activity of epitope-tagged adenylate cyclase of Bordetella pertussis allows in vitro presentation of a foreign epitope to CD8+ cytotoxic T cells. Infect Immun (1995) 1.17
Priming of anti-human immunodeficiency virus (HIV) CD8+ cytotoxic T cells in vivo by carrier-free HIV synthetic peptides. Proc Natl Acad Sci U S A (1991) 1.16
Induction of long-term memory CD8(+) T cells for recall of viral clearing responses against influenza virus. J Virol (2002) 1.12
Peptide-induced T-cell tolerance to prevent autoimmune diabetes in a transgenic mouse model. Proc Natl Acad Sci U S A (1994) 1.12
Poliovirus-specific major histocompatibility complex class I-restricted cytolytic T-cell epitopes in mice localize to neutralizing antigenic regions. J Virol (1992) 1.03
Cationic lipids direct a viral glycoprotein into the class I major histocompatibility complex antigen-presentation pathway. Proc Natl Acad Sci U S A (1992) 1.00
Induction of a polarized Th1 response by insertion of multiple copies of a viral T-cell epitope into adenylate cyclase of Bordetella pertussis. Infect Immun (2000) 0.98
Induction of primary, antiviral cytotoxic, and proliferative responses with antigens administered via dendritic cells. J Virol (1993) 0.97
Simian virus 40 T antigen as a carrier for the expression of cytotoxic T-lymphocyte recognition epitopes. J Virol (1993) 0.96
T cell responses to viral infections - opportunities for Peptide vaccination. Front Immunol (2014) 0.95
Peptide Vaccine: Progress and Challenges. Vaccines (Basel) (2014) 0.94
Vaccination with a synthetic peptide modulates lymphocytic choriomeningitis virus-mediated immunopathology. J Virol (1992) 0.93
Induction of feline immunodeficiency virus-specific cytotoxic T cells in vivo with carrier-free synthetic peptide. J Virol (1994) 0.93
Induction of protective cytotoxic T cells to murine cytomegalovirus by using a nonapeptide and a human-compatible adjuvant (Montanide ISA 720). J Virol (1995) 0.93
Delivery of multiple epitopes by recombinant detoxified adenylate cyclase of Bordetella pertussis induces protective antiviral immunity. J Virol (2001) 0.93
Skin test to assess virus-specific cytotoxic T-cell activity. Proc Natl Acad Sci U S A (1992) 0.93
Induction of feline immunodeficiency virus-specific cell-mediated and humoral immune responses following immunization with a multiple antigenic peptide from the envelope V3 domain. Immunology (1995) 0.92
Intranasal delivery of recombinant parvovirus-like particles elicits cytotoxic T-cell and neutralizing antibody responses. J Virol (1999) 0.88
Identification of HIV protein-derived cytotoxic T lymphocyte (CTL) epitopes for their possible use as synthetic vaccine. Clin Exp Immunol (1995) 0.84
Artificial mosaic protein containing antigenic epitopes of hepatitis E virus. J Virol (1994) 0.82
Induction of cytotoxic T-cell response by optimal-length peptides does not require CD4+ T-cell help. Immunology (1996) 0.81
Multispecific and heterogeneous recognition of the gag protein by cytotoxic T lymphocytes (CTL) from HIV-infected patients: factors other than the MHC control the epitopic specificities. Clin Exp Immunol (1994) 0.80
Adoptive immunity mediated by HLA-A*0201 restricted Asp f16 peptides-specific CD8+ T cells against Aspergillus fumigatus infection. Eur J Clin Microbiol Infect Dis (2012) 0.77
Vaccination with lipid core peptides fails to induce epitope-specific T cell responses but confers non-specific protective immunity in a malaria model. PLoS One (2012) 0.77
Designing therapeutic cancer vaccines by mimicking viral infections. Cancer Immunol Immunother (2016) 0.75
The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell (1986) 14.96
Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature (1974) 13.24
Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature (1985) 9.62
The virology and immunobiology of lymphocytic choriomeningitis virus infection. Adv Immunol (1980) 6.24
In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature (1989) 5.08
Molecular analyses of a five-amino-acid cytotoxic T-lymphocyte (CTL) epitope: an immunodominant region which induces nonreciprocal CTL cross-reactivity. J Virol (1989) 2.79
Induction of ovalbumin-specific cytotoxic T cells by in vivo peptide immunization. J Exp Med (1989) 2.74
Major histocompatibility complex--dependent T cell epitopes of lymphocytic choriomeningitis virus nucleoprotein and their protective capacity against viral disease. Eur J Immunol (1989) 2.71
Antigen presentation pathways to class I and class II MHC-restricted T lymphocytes. Immunol Rev (1987) 2.64
Cytotoxic T lymphocytes against a soluble protein. Nature (1987) 2.36
p-alkoxybenzyl alcohol resin and p-alkoxybenzyloxycarbonylhydrazide resin for solid phase synthesis of protected peptide fragments. J Am Chem Soc (1973) 1.87
Class I MHC can present an endogenous peptide to cytotoxic T lymphocytes. J Exp Med (1989) 1.54
Product of a transferred H-2Ld gene acts as restriction element for LCMV-specific killer T cells. Nature (1982) 1.50
Class I-restricted presentation occurs without internalization or processing of exogenous antigenic peptides. J Immunol (1989) 1.49
Induction of class I MHC-restricted, peptide-specific cytolytic T lymphocytes by peptide priming in vivo. J Immunol (1989) 1.19
Functional role of type I and type II interferons in antiviral defense. Science (1994) 18.92
MHC-restricted cytotoxic T cells: studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction-specificity, function, and responsiveness. Adv Immunol (1979) 15.58
Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature (1974) 13.24
Immune response in mice that lack the interferon-gamma receptor. Science (1993) 12.15
Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature (1994) 11.22
Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature (1993) 9.81
On the thymus in the differentiation of "H-2 self-recognition" by T cells: evidence for dual recognition? J Exp Med (1978) 9.51
Specificity of virus-immune effector T cells for H-2K or H-2D compatible interactions: implications for H-antigen diversity. Transplant Rev (1976) 8.10
Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen. Nature (1989) 7.52
Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science (1994) 7.34
Immunological surveillance against altered self components by sensitised T lymphocytes in lymphocytic choriomeningitis. Nature (1974) 6.99
Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell (1991) 6.49
Normal development and function of CD8+ cells but markedly decreased helper cell activity in mice lacking CD4. Nature (1991) 5.98
A primitive T cell-independent mechanism of intestinal mucosal IgA responses to commensal bacteria. Science (2000) 5.78
Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes. J Exp Med (1998) 5.78
Viral escape by selection of cytotoxic T cell-resistant virus variants in vivo. Nature (1990) 5.41
Evidence for a differential avidity model of T cell selection in the thymus. Cell (1994) 5.24
Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell (1996) 4.74
Control of early viral and bacterial distribution and disease by natural antibodies. Science (1999) 4.73
T-cell-mediated immunopathology in viral infections. Transplant Rev (1974) 4.72
Genes required for cytotoxicity against virus-infected target cells in K and D regions of H-2 complex. Nature (1975) 4.41
Enhanced establishment of a virus carrier state in adult CD4+ T-cell-deficient mice. J Virol (1994) 4.34
The lymphoreticular system in triggering virus plus self-specific cytotoxic T cells: evidence for T help. J Exp Med (1978) 4.27
Antiviral defense in mice lacking both alpha/beta and gamma interferon receptors. J Virol (1995) 4.16
H-2 compatibility is required for T-cell-mediated lysis of target cells infected with lymphocytic choriomeningitis virus. J Exp Med (1975) 4.16
T-cell receptor V beta use predicts reactivity and tolerance to Mlsa-encoded antigens. Nature (1988) 4.04
Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature (2001) 3.99
Original antigenic sin impairs cytotoxic T lymphocyte responses to viruses bearing variant epitopes. Nature (1998) 3.78
Quantification of lymphocytic choriomeningitis virus with an immunological focus assay in 24- or 96-well plates. J Virol Methods (1991) 3.78
Antigen localization and migration in immunity and tolerance. N Engl J Med (1998) 3.71
Virus-specific MHC-class II-restricted TCR-transgenic mice: effects on humoral and cellular immune responses after viral infection. Eur J Immunol (1998) 3.52
Enhanced immunological surveillance in mice heterozygous at the H-2 gene complex. Nature (1975) 3.49
A biological role for the major histocompatibility antigens. Lancet (1975) 3.40
The influence of antigen organization on B cell responsiveness. Science (1993) 3.32
Immune responses in interleukin-2-deficient mice. Science (1993) 3.29
On immunity against infections and vaccines: credo 2004. Scand J Immunol (2004) 3.29
Fine specificity of a continuously growing killer cell clone specific for H-Y antigen. Eur J Immunol (1979) 3.27
IgA production without mu or delta chain expression in developing B cells. Nat Immunol (2001) 3.26
Visualization, characterization, and turnover of CD8+ memory T cells in virus-infected hosts. J Exp Med (1996) 3.26
Occupational exposure assessment in case-control studies: opportunities for improvement. Occup Environ Med (2002) 3.21
On immunological memory. Annu Rev Immunol (1996) 3.21
A crucial role for B cells in neuroinvasive scrapie. Nature (1998) 3.19
Histological analysis of CD11c-DTR/GFP mice after in vivo depletion of dendritic cells. Clin Exp Immunol (2005) 3.12
Functional analysis of T lymphocyte subsets in antiviral host defense. J Immunol (1987) 3.11
Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides. J Exp Med (1998) 3.03
Decreased tumor surveillance in perforin-deficient mice. J Exp Med (1996) 3.00
Immune defence in mice lacking type I and/or type II interferon receptors. Immunol Rev (1995) 2.97
Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo. Annu Rev Immunol (1996) 2.96
Neutralizing antiviral B cell responses. Annu Rev Immunol (1997) 2.86
SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation (1997) 2.80
Major histocompatibility complex--dependent T cell epitopes of lymphocytic choriomeningitis virus nucleoprotein and their protective capacity against viral disease. Eur J Immunol (1989) 2.71
H-2 restriction of cell-mediated immunity to an intracellular bacterium: effector T cells are specific for Listeria antigen in association with H-21 region-coded self-markers. J Exp Med (1977) 2.71
Gene technology and democracy. Science (1997) 2.68
Lower receptor avidity required for thymic clonal deletion than for effector T-cell function. Nature (1991) 2.66
Wnt 5a signaling is critical for macrophage-induced invasion of breast cancer cell lines. Proc Natl Acad Sci U S A (2006) 2.60
Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity. Immunol Rev (1997) 2.58
A non-retroviral RNA virus persists in DNA form. Nature (1997) 2.57
Thymus and lymphohemopoietic cells: their role in T cell maturation in selection of T cells' H-2-restriction-specificity and in H-2 linked Ir gene control. Immunol Rev (1978) 2.56
On the role of antigen in maintaining cytotoxic T-cell memory. Proc Natl Acad Sci U S A (1996) 2.55
Cytotoxic T cells learn specificity for self H-2 during differentiation in the thymus. Nature (1978) 2.51
Self antigens expressed by solid tumors Do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J Exp Med (1997) 2.47
The roles of perforin- and Fas-dependent cytotoxicity in protection against cytopathic and noncytopathic viruses. Eur J Immunol (1995) 2.47
Structure and function of human perforin. Nature (1988) 2.47
The role of antibody concentration and avidity in antiviral protection. Science (1997) 2.45
H-2 restriction of virus-specific cytotoxicity across the H-2 barrier. Separate effector T-cell specificities are associated with self-H-2 and with the tolerated allogeneic H-2 in chimeras. J Exp Med (1976) 2.45
Characteristics of the interaction in vitro between cytotoxic thymus-derived lymphocytes and target monolayers infected with lymphocytic choriomeningitis virus. Scand J Immunol (1974) 2.42
Virus-triggered acquired immunodeficiency by cytotoxic T-cell-dependent destruction of antigen-presenting cells and lymph follicle structure. Proc Natl Acad Sci U S A (1991) 2.41
PrP expression in B lymphocytes is not required for prion neuroinvasion. Nat Med (1998) 2.40
Assignment of genes for immunoglobulin kappa and heavy chains to chromosomes 6 and 12 in mouse. Proc Natl Acad Sci U S A (1978) 2.38
Purification and characterization of a cytolytic pore-forming protein from granules of cloned lymphocytes with natural killer activity. Cell (1986) 2.38
Natural antibodies and complement link innate and acquired immunity. Immunol Today (2000) 2.37
Restriction by H-2 gene complex of transfer of cell-mediated immunity to Listeria monocytogenes. Nature (1974) 2.35
Complement facilitates early prion pathogenesis. Nat Med (2001) 2.30
Intrathymic deletion of self-reactive cells prevented by neonatal anti-CD4 antibody treatment. Nature (1988) 2.28